Quick Facts: Cintilan

• Used for: The management of metastatic colorectal cancer.
• Purpose: Intended to contribute to overall disease control.
• Context: Employed in patients who have received prior lines of chemotherapy.

Cintilan is a therapeutic compound used in the management of refractory metastatic colorectal cancer (mCRC). The agent is intended to contribute to the overall management strategy for adult patients whose disease has progressed following prior systemic treatments, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as anti-VEGF therapy.

The use of Cintilan is indicated for this specific patient population. It is considered a treatment option employed by oncologists when other standard-of-care treatments have been exhausted. The goal of treatment with Cintilan is to assist in disease control and support continued care.

Who Can and Cannot Use Cintilan? — Official Regulatory Information

Official regulatory labeling dictates specific populations for whom the use of Cintilan (Piracetam) is either prohibited or restricted.

Connection to the overall eligibility profile

Regulatory documents strictly define who can and cannot use Cintilan by establishing absolute contraindications based on clinical conditions and specific diseases [Source 2.1]. Eligibility for patients with less severe renal impairment or for older adults is conditional, requiring mandatory monitoring and dose restriction to maintain safety parameters [Source 3.4]. Use in pediatric, pregnant, and breastfeeding populations is generally not recommended, reflecting limitations in established regulatory data [Source 2.5].

Interactions with other medicines and products

Official regulatory documents require careful consideration of co-administered substances due to the potential for clinically significant drug interactions with Cintilan. These interactions are categorized based on their severity and clinical consequence, as documented by health authorities.

Contraindicated and Restricted Combinations

Cintilan must not be used during or within 14 days following the administration of Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertensive crisis. Additionally, coadministration with any other prescribed, over-the-counter, or herbal product intended for weight loss is not recommended.

Pharmacodynamic and Endocrine Interactions

Cintilan may decrease the blood pressure-lowering effect of Adrenergic Neuron Blocking Drugs. For patients managing diabetes, a reduction in the required dosage of Insulin or oral hypoglycemic medications may be necessary, as the requirements for these medications may be altered by Cintilan. Concomitant use of alcohol may result in an adverse drug reaction.

Summary of Interaction Profile

All patients should inform their healthcare provider of all current medications, including supplements and herbal products, to ensure safe co-administration based on the established regulatory profile.

Cintilan (Piracetam) modulates various cellular and systemic physiological processes. The compound influences neuronal and vascular function, though its specific primary molecular target is not definitively characterized. Mechanistically, it interacts with neuronal membranes, altering their physical properties. This modification of membrane fluidity and structure is associated with enhanced neurotransmission across multiple brain regions, particularly within the cerebral cortex. The drug is observed to increase the density of muscarinic cholinergic receptors and facilitates the activity of the glutamatergic system, including AMPA and NMDA receptors. Intracellularly, it promotes enhanced oxidative glycolysis and increases the turnover of adenosine triphosphate (ATP) within neuronal tissue. Furthermore, at the systemic level, Cintilan modifies hemorheological parameters, including reduced platelet aggregation and enhanced erythrocyte deformability, resulting in a modulation of microcirculatory blood flow.

How to Use Cintilan

Cintilan is administered via multiple routes to accommodate clinical needs, primarily through oral forms (tablets or solution) and parenteral routes, including intravenous (IV) injection or infusion, and in some contexts, intramuscular (IM) injection. The availability of different dosage forms establishes flexibility, allowing the parenteral route to be used when oral intake is temporarily compromised.

Dosing and Frequency

For specific approved neurological conditions, a standardized, high-level regimen is used. Treatment typically begins with an initial daily dose of 7.2 grams. The daily amount is then gradually increased, or titrated, by an additional 4.8 grams every three to four days until the desired maintenance dose is achieved, not to exceed a maximum daily intake of 24 grams. The total daily dose must be divided into multiple sub-doses, usually two to four, to be taken throughout the day. Oral forms may be consumed with or without food.

Administration Constraints

The use protocol for Cintilan is defined by its long-term nature and strictly controlled procedural steps. The treatment must not be stopped abruptly. Instead, standard protocols require a slow, controlled tapering process, often involving a reduction of 1.2 grams every two to four days. Additionally, a patient’s dose and frequency must be precisely adjusted based on renal function (Creatinine Clearance) to ensure appropriate administration. The injectable solution may be prepared for administration as a continuous IV infusion over 24 hours.

Research Evidence / Overview of Studies for Cintilan

Evidence for Use in Refractory Metastatic Colorectal Cancer (mCRC)

Cintilan was studied for use in refractory metastatic colorectal cancer in international, multicenter Randomized Controlled Trials (RCTs). These studies were evaluated in adult patients whose cancer had progressed despite receiving the standard sequence of prior therapies. Research examined whether patterns related to disease progression and survival were observed in patients receiving Cintilan compared to those receiving best supportive care or a placebo.

The main outcomes evaluated in these pivotal trials were survival measures, including Overall Survival (OS) and Progression-Free Survival (PFS), which track the time until death or disease worsening. Studies also monitored Objective Response Rate (ORR) and Disease Control Rate (DCR). The evidence was observed in highly controlled settings, and findings describe group patterns, not personal outcomes.

Long-Term Research and Durability of Response

Research exploring the effects of Cintilan primarily focuses on the short-term and intermediate-term changes measured during the study period. Following the main treatment phase, researchers often conducted long-term follow-up to continue monitoring survival data. However, the long-term effects are not fully established, and there is limited information regarding patterns of systemic function after the study period.

Research in Specific Patient Groups (Special Populations)

Cintilan was evaluated in adult participants with metastatic colorectal cancer, focusing on cohorts considered heavily pre-treated. Data for certain groups, such as those with unique co-existing health conditions (comorbidities), remain insufficient. Furthermore, the primary research provides limited context for how patients who have not been pre-treated with the full standard regimen may respond.

The Landscape of Clinical Evidence: Uncertainty and Gaps

The overall evidence for Cintilan was evaluated in trials that included randomized controlled designs, but certainty remains low in several practical areas. Key limitations include that the results apply only to the populations studied, which were specific cohorts resistant to other therapies. Follow-up durations were limited by the short median survival windows, and data for certain groups remain insufficient, highlighting the need for ongoing research.

Key Studies & References Colorectal cancer (NICE guideline NG151) - Reference for clinical management, patient populations, and follow-up standards

Common questions about Cintilan (FAQ)

Q: What is Cintilan primarily used to treat according to official documents?

Official regulatory documents indicate that the active ingredient in Cintilan is used to treat cortical myoclonus, a type of movement disorder. The medicine may also be used to address symptoms associated with cerebral insufficiency (impaired brain function). The exact approved conditions may vary based on local regulatory authority.

Q: Is Cintilan known to affect patterns of sleep or wakefulness?

Official safety documents list several sleep-related issues as possible side effects. These include sleep disturbances, insomnia (difficulty sleeping), and, conversely, some patients may experience sleepiness or nervousness. These are possible adverse reactions reported in the official information.

Q: Are the side effects of Cintilan known to lessen after the first few weeks?

Regulatory information indicates that common adverse reactions are typically mild and temporary. For many individuals, these effects may subside over time as the body adjusts to the medicine. The full list of potential effects is described in the official prescribing information.

Q: Does Cintilan have an effect on blood pressure or heart rate?

Official safety reports have indicated that an increase in blood pressure has been reported as a side effect. Regulatory documents indicate that patients with pre-existing heart conditions may require careful consideration when using the medicine.

Q: What does it mean if Cintilan has a 'Warning' in its documentation?

The Warnings and Precautions sections of official documents are used to alert users to serious hazards or risks of the medicine. Warnings outline situations where close monitoring, specific precautions, or adjustments to use may be necessary.

Q: What information is available regarding skin rashes or allergic reactions to Cintilan?

Cintilan is contraindicated (should not be used) in patients who are allergic to the active substance or its derivatives. Official adverse event reporting includes skin rash, swelling, and other types of allergic reactions. Official documentation details the signs of a severe allergic reaction that warrant immediate medical attention.

Q: What should I know about headaches while taking Cintilan?

According to official product information, headache is listed as a common or very common side effect of Cintilan. Headaches, if persistent or severe, are considered symptoms that should be medically reviewed.

Q: Does Cintilan interact with common over-the-counter medicines like ibuprofen or acetaminophen?

The official documents warn of potential interactions with drugs that slow blood clotting, such as certain anticoagulants. The official documentation emphasizes the importance of a healthcare provider being aware of all co-administered medicines, including non-prescription pain relievers.

Q: Can herbal supplements like St. John's Wort or ginkgo biloba be taken with Cintilan?

Regulatory information notes that healthcare providers should be informed of any co-administered herbal or complementary medicines, as potential interactions may exist. This allows for a proper review of the combination.

Q: Are there any specific foods that are known to interact with Cintilan?

Official regulatory documents confirm that Cintilan tablets can generally be taken with or without food. No specific foods, juices, or dietary restrictions are listed in the product information as known to interact with the medicine.

Q: Does Cintilan have any known effect on standard lab or blood test results?

Official information states that Cintilan has been observed to affect certain coagulation factors in the blood. This includes increasing bleeding time and reducing plasma levels of fibrinogen. Blood cell counts are monitored regularly during use.

Q: Is there an interaction warning between Cintilan and common cold or cough remedies?

Official documentation indicates that a healthcare provider should be informed of all current medications, including those used for cold or cough symptoms, to allow for a comprehensive review.

Q: What is the clearance or half-life of Cintilan?

The elimination plasma half-life of Cintilan is reported to be approximately 5.0 hours in healthy young adults. This value indicates how quickly the substance is cleared from the bloodstream. It is excreted almost completely through the urine.

Q: How is Cintilan different from other drugs described as treating the same condition?

Cintilan is noted for influencing both neuronal and vascular function. Its specific mechanism involves improving the fluidity of nerve cell membranes and enhancing chemical communication in the brain, which establishes its unique pharmacological role in its class.

Q: Is there a known potential for dependency or withdrawal symptoms associated with Cintilan?

Official instructions state that the medicine should not be stopped suddenly. Gradual dose reduction (tapering) is required to avoid adverse effects like a sudden return of symptoms or potentially withdrawal seizures. This method helps the body adjust slowly.

Q: Why do official documents advise caution or supervision when stopping the use of Cintilan?

Official documents advise caution because abrupt discontinuation can cause a relapse of symptoms or result in new effects like twitching and jerking (withdrawal seizures). The required gradual reduction should occur under the direction of a healthcare professional.

Q: Does Cintilan require any special storage conditions at home?

Official pharmaceutical guidelines require that the medicine be stored in its original container, in a dry place at room temperature (e.g., 15 C to 25 C), unless otherwise instructed. Specific storage details are provided on the product packaging.

Q: What should I do if I think I missed a dose of Cintilan?

According to the patient information leaflet, if a dose is forgotten, the patient should not take a double dose to make up for it. Instead, they should simply take the next scheduled dose at the usual time as planned.

Q: How is Cintilan's effect on driving or operating machinery described in the warnings?

The official product information warns that the medicine may cause effects such as drowsiness and shakiness. The presence of these effects may impair a patient's ability to drive or operate machinery, as noted in the official warnings.

How to Store and Dispose of Cintilan?

Specific official storage, handling, and disposal instructions for the medication Cintilan must be followed as described on the product's official packaging or the patient information leaflet provided by the manufacturer. These details are determined by stability data and regulatory documents, such as those from the FDA or EMA.

The most recommended method for disposing of unused or expired medications is using a formal drug take-back program, which may include drug take-back days or permanent collection sites at pharmacies or police stations. If a take-back option is unavailable, the general FDA guidance recommends mixing the medication with an undesirable substance, sealing it in a container, and placing it in household trash, after scratching out all personal information on the label.